Cargando…

Binary Polymeric Surfactant Mixtures for the Development of Novel Loteprednol Etabonate Nanomicellar Eyedrops

The treatment of several ocular inflammatory conditions affecting different areas of the ocular globe involves the administration of topical ophthalmic formulations containing corticosteroids. This research was aimed at evaluating the solubilising efficacy of 5.0% w/w of different binary mixtures of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tampucci, Silvia, Monti, Daniela, Burgalassi, Susi, Terreni, Eleonora, Paganini, Valentina, Di Gangi, Mariacristina, Chetoni, Patrizia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305198/ https://www.ncbi.nlm.nih.gov/pubmed/37375811 http://dx.doi.org/10.3390/ph16060864

Ejemplares similares

Combination of Nanomicellar Technology and In Situ Gelling Polymer as Ocular Drug Delivery System (ODDS) for Cyclosporine-A
por: Terreni, Eleonora, et al.
Publicado: (2021)

Assembling Surfactants-Mucoadhesive Polymer Nanomicelles (ASMP-Nano) for Ocular Delivery of Cyclosporine-A
por: Terreni, Eleonora, et al.
Publicado: (2020)

Sporopollenin Microcapsule: Sunscreen Delivery System with Photoprotective Properties
por: Tampucci, Silvia, et al.
Publicado: (2022)

Nanostructured Drug Delivery Systems for Targeting 5-α-Reductase Inhibitors to the Hair Follicle
por: Tampucci, Silvia, et al.
Publicado: (2022)

Loteprednol Etabonate for the Treatment of Dry Eye Disease
por: Beckman, Kenneth, et al.
Publicado: (2020)

Effect of 5-Oxo-2-Pyrrolidinecarboxylic Acid (PCA) as a New Topically Applied Agent for Dry Eye Syndrome Treatment
por: Tampucci, Silvia, et al.
Publicado: (2018)

Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate
por: Comstock, Timothy L., et al.
Publicado: (2012)

An update on the surgical management of pterygium and the role of loteprednol etabonate ointment
por: Sheppard, John D, et al.
Publicado: (2014)

Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure
por: Sheppard, John D., et al.
Publicado: (2016)

Development and Characterization of a Novel Peptide-Loaded Antimicrobial Ocular Insert
por: Terreni, Eleonora, et al.
Publicado: (2020)

Ocular Application of Oleuropein in Dry Eye Treatment: Formulation Studies and Biological Evaluation
por: Burgalassi, Susi, et al.
Publicado: (2021)

Hydrogels as Corneal Stroma Substitutes for In Vitro Evaluation of Drug Ocular Permeation
por: Burgalassi, Susi, et al.
Publicado: (2022)

Ciclopirox Hydroxypropyl Chitosan (CPX-HPCH) Nail Lacquer and Breathable Cosmetic Nail Polish: In Vitro Evaluation of Drug Transungual Permeation Following the Combined Application
por: Monti, Daniela, et al.
Publicado: (2022)

Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation
por: Schopf, Lisa, et al.
Publicado: (2014)

Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis
por: Mah, Francis S., et al.
Publicado: (2021)

Loteprednol etabonate: Dematiaceous fungal colonisation by Bipolaris species in the left eye: case report
Publicado: (2020)

pH-Responsive Nanostructures Based on Surface Active Fatty Acid-Protic Ionic Liquids for Imiquimod Delivery in Skin Cancer Topical Therapy
por: Tampucci, Silvia, et al.
Publicado: (2020)

Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use
por: Amon, Michael, et al.
Publicado: (2012)

A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
por: Khaimi, Mahmoud A
Publicado: (2018)

Comparison between Betamethasone, Fluorometholone and Loteprednol Etabonate on intraocular pressure in patients after keratorefractive surgery
por: Shokoohi-Rad, Saeed, et al.
Publicado: (2017)

Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%
por: Cavet, Megan E., et al.
Publicado: (2019)

Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease
por: Venkateswaran, Nandini, et al.
Publicado: (2022)

Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
por: Comstock, Timothy L, et al.
Publicado: (2011)

Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients
por: Özcan, Gökçen, et al.
Publicado: (2021)

Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial
por: Fong, Raymond, et al.
Publicado: (2012)

Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
por: Coffey, Martin J, et al.
Publicado: (2013)

Dose Uniformity of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38% Compared with Prednisolone Acetate Ophthalmic Suspension 1%
por: Marlowe, Zora T., et al.
Publicado: (2021)

Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%)
por: Marlowe, Zora T, et al.
Publicado: (2014)

Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery
por: Kang, Connie, et al.
Publicado: (2020)

Correction to: Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Infammation and Pain Following Ocular Surgery
por: Kang, Connie, et al.
Publicado: (2020)

Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions
por: Deom, James E, et al.
Publicado: (2022)

Polymeric worm-like nanomicellar system for accelerated wound healing
por: Singh, Aarti, et al.
Publicado: (2020)

A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery
por: Salinger, Clifford L, et al.
Publicado: (2015)

Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery
por: Sheppard, JD, et al.
Publicado: (2019)

Ciclopirox and Efinaconazole Transungual Permeation, Antifungal Activity, and Proficiency To Induce Resistance in Trichophyton rubrum
por: Monti, Daniela, et al.
Publicado: (2019)

Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies
por: Fong, Raymond, et al.
Publicado: (2019)

Arabinogalactan as Active Compound in the Management of Corneal Wounds: In Vitro Toxicity and In Vivo Investigations on Rabbits
por: Burgalassi, Susi, et al.
Publicado: (2011)

Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle‐controlled study
por: Liu, Rui‐fen, et al.
Publicado: (2016)

Diclofenac-Derived Hybrids for Treatment of Actinic Keratosis and Squamous Cell Carcinoma
por: Tampucci, Silvia, et al.
Publicado: (2019)

Nanomicellar Extraction of Polyphenols—Methodology and Applications Review
por: Śliwa, Paweł, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pft7d86vhdm9pbcadmndcfvdrd